Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/164999
Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
DARBÀ, Josep, et al. Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials. Revista Portuguesa de Diabetes. 2019. Vol. 14, num. 4, pags. 141-150. ISSN 1646-3439. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/164999